ASX Health Stocks: dorsaVi gets ISO certification; Actinogen to begin Phase 2 trial
Health & Biotech
Health & Biotech
Link copied to
Motion analysis device maker dorsaVi (ASX:DVL) has been awarded the internationally recognised ISO 27001 certification, verifying the data security standards for the company .
The ISO 27001 standard specifies advanced information security and data privacy requirements for organisations, and certification is commonly a prerequisite to partnering with top tier local and global institutions.
This certification cements dorsaVi’s position in the wearable sensor market, as it is one of the first companies to receive it, the company said, and it combines with DVL’s existing ISO 13485 certification, FDA and CE Mark approvals.
“While there are many types of wearable sensors available on the market currently, few are able to deliver the high standard of data privacy required to work with leading global institutions such as Medtronic and Stryke,” said dorsaVi CEO Dr Andrew Ronchi.
“dorsaVi’s focus on providing the best ‘medical grade’ wearable sensor technology puts us in a unique category, and is one of the reasons these big companies keep choosing us.”
dorsaVi says that using its devices, many aspects of detailed human movement can be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24hours.
Neurological specialist Actinogen (ASX:ACW) has appointed leading clinical research organisation Worldwide Clinical Trial to manage the implementation of its upcoming XanaFX Phase 2 trial.
The XanaFX Phase 2 trial will study adolescent boys and young adults with Fragile X Syndrome (FXS), by using Actinogen’s novel small-molecule drug, Xanamem.
Worldwide is a global clinical research organisation specialising in neurological, paediatric, and rare diseases.
The company will help Actinogen manage the recruitment, and conduct and general aspects of the trial.
“There are currently no treatments approved anywhere in the world for FXS, and the commencement of Actinogen’s key XanaFX trial is another important step in our quest to help make a material difference to the quality of life for people and their families living with FXS,” says Dr Steven Gourlay, Actinogen CEO.
Results are expected in 2023.